A new antidiabetic agent (JTT-501) rapidly stimulates glucose disposal rates by enhancing insulin signal transduction in skeletal muscle

Diabetologia

Volumn 42, Issue 2, 1999, Pages 151-159

  Maegawa, H ^a   Obata, T ^a   Shibata, T ^b   Fujita, T ^a   Ugi, S ^a   Morino, K ^a   Nishio, Y ^a   Kojima, H ^a   Hidaka, H ^a   Haneda, M ^a   Yasuda, H ^a   Kikkawa, R ^a   Kashiwagi, A ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b Japan Tabacco Inc   (Japan)

Author keywords

Euglycaemic insulin clamp; Insulin sensitizer; Insulin signaling; Isoxazolidinedione; JTT 501

Indexed keywords

ANTIDIABETIC AGENT; GLYCOGEN SYNTHASE; ISOXAZOLIDINE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PIOGLITAZONE; RECEPTOR SUBUNIT; REGLITAZAR; TROGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; GLUCOSE INFUSION; GLUCOSE METABOLISM; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; INSULIN SENSITIVITY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SOLEUS MUSCLE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; BLOOD GLUCOSE; DRUG SYNERGISM; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; HYPERINSULINISM; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIC AGENTS; IMMUNOSORBENT TECHNIQUES; INSULIN; ISOXAZOLES; MALE; MUSCLE, SKELETAL; PHOSPHOTYROSINE; RATS; RATS, SPRAGUE-DAWLEY; RATS, ZUCKER; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION;

EID: 0032896695     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051133     Document Type: Article

References (31)

1. 1. DeFronzo RA, Bonadonna RC, Ferrannini BE (1992) Pathogenesis of NIDDM. Diabetes Care 15: 318-368
2. 2. Arner P, Pollare T, Lithell H, Livingstone JN (1987) Defective insulin receptor tyrosine kinase in human skeletal muscle in obesity and type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 30: 437-440
3. 3. Caro J F, Shinha MK, Raju SM et al. (1987) Insulin receptor kinase in human skeletal muscle from obese subjects with and without non insulin dependent diabetes. J Clin Invest 79: 1330-1337
4. 4. Obermaiser-Kusser B, White MF, Pongrats D et al. (1989) A defective intramolecular autoactivation cascade may cause the reduced kinase activity of the skeletal muscle insulin receptor from patients with non-insulin-dependent diabetes mellitus. J Biol Chem 264: 9497-9504
5. 5. Maegawa H, Shigeta Y, Egawa K, Kobayashi M (1991) Impaired autophosphorylation of insulin receptors from abdominal skeletal muscles in non-obese subjects with NID-DM. Diabetes 40: 815-819
6. 6. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H (1988) Characterization of new oral antidiabetic agent CS-045. Diabetes 37: 1549-1558
7. 7. Sugiyama Y, Taketomi S, Shimura Y, Ikeda H, Fujita T (1990) Effect of pioglitazone on glucose and lipid metabolism in Wistar fatty rats. Arznein-Forsch 40: 263-267
8. 8. Saltiel AR, Olefsky JM (1996) Thiazolidinediones in the treatment of insulin resistance and Type II diabetes. Diabetes 45: 1661-1669
9. 9. Lee M-K, Olefsky JM (1995) Acute effects of troglitazone on in vivo insulin action in normal rats. Metabolism 44: 1166-1169
10. 10. Ugi S, Maegawa H, Kashiwagi A, Adachi M, Olefsky JM, Kikkawa R (1996) Expression of dominant negative mutant SHPTP2 attenuates phosphatidylinositol 3-kinase activity via modulation of phosphorylation of insulin receptor substrate-1. J Biol Chem 271: 12595-12602
11. 11. Terasaki J, Anai M, Funaki M et al. (1998) Role of JTT-501, a new insulin sensitiser, in restoring impaired GLUT4 translocation in adipocytes of rats fed a high fat diet. Diabetologia 41: 400-409
12. 12. McClain DA, Maegawa H, Lee J, Dull TJ, Ullrich A, Olefsky JM (1987) A mutant insulin receptor with defective tyrosine kinase displays no biologic activity and does not undergo endocytosis. J Biol Chem 262: 14663-14671
13. 13. Kobayashi M, Iwanishi M, Egawa K, Maegawa H, Shigeta Y (1991) A new oral antidiabetic agent (CS-045) increased kinase activity of insulin receptors from skeletal muscles of Zucker fatty rats. In: Sakamoto N, Angel A, Hotta N (eds) New directions in research and clinical works for obesity and diabetes mellitus. Excerpta media, Amsterdam, pp181-185
14. 14. Kobayashi M, Iwanishi M, Egawa K, Shigeta Y(1992) Pioglitazone increases insulin sensitivity by activating insulin receptor kinase. Diabetes 41: 476-483
15. 15. Iwanishi M, Kobayashi M (1993) Effects of pioglitazone on insulin receptors from skeletal muscles of high-fat fed rats. Metabolism 42: 1017-1021
16. 16. Hayakawa T, Shiraki T, Morimono T, Shii K, Ikeda H (1996) Pioglitazone improves insulin signaling defects in skeletal mulches from Wistar Fatty (fa/fa) rats. Biochem Biophys Res Comun 223: 439-444
17. 17. Okuno A, Ikeda K, Shiota M et al. (1997) Acute effect of troglitazone on glucose metabolism in the absence or presence of insulin in perfused rat hindlimb. Metabolism 46: 716-721
18. 18. Furnsinn C, Neschen S, Noe C et al. (1997) Acute non-insulin-like stimulation of rat muscle glucose metabolism by troglitazone in vitro. Br J Pharmacol 122: 1367-1374
19. 19. Ciaraldi TP, Huber-Knudsen K, Hickman M, Olefsky JM (1995) Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents. Metabolism 44: 976-982
20. 20. Spiegelman BM (1998) PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 47: 507-514
21. 21. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer ASA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ) J Biol Chem 270: 12953-12956
22. 22. Hotamisligil GS, Spiegelman BM (1994) Tumor necrosis factor α: a key component of the obesity-diabetes link. Diabetes 43: 1271-1278
23. 23. Szalkowski D, White-Carrington S, Berger J, Zhang B (1995) Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-a on differentiation, insulin-stimulated glucose uptake and gene expression in 3T3-L1 cells. Endocrinology 136: 1474-1481
24. 24. Burant CF, Sreenan S, Hirano K et al. (1997) Troglitazone action is independent of adipose tissue J Clin Invest 100: 2900-2908
25. 25. Kellerer M, Kroder G, Tippmer S et al. (1994) Troglitazone prevents glucose-induced insulin resistance of insulin receptor in Rat-1 fibroblasts. Diabetes 43: 447-453
26. 26. Maegawa H, Ide R, Hasegawa M et al. (1995) Thiazolidine derivatives ameliorate glucose induced insulin resistance via the normalization of protein tyrosine phosphatase activities. J Biol Chem 270: 7724-7730
27. 27. Song J, Walsh MF, Igwe R et al. (1997) Troglitazone reduces contraction by inhibition of vascular smooth muscle cell Ca2 + currents and not endothelial nitric oxide production. Diabetes 46: 659-664
28. 28. Zhang B, Szalkowski D, Diaz E, Hayes N, Smith R, Berger J (1994) Potentiation of insulin stimulation of phosphatidylinositol 3-kinase by thiazolidinedione-derived antidiabetic agents in Chinese hamster ovary cells expressing human insulin receptors and L6 myotube. J Biol Chem 269: 25735-25741
29. 29. Ahmad F, Glodstein BJ (1995) Increased abundance of specific skeletal muscle protein-tyrosine phosphatases in a genetic model of insulin-resistant obesity and diabetes mellitus. Metabolism 44: 1175-1184
30. 30. McGuire MC, Fields RM, Nyomba BL et al. (1991) Abnormal regulation of protein tyrosine phosphatase activities in skeletal muscle of insulin-resistant human. Diabetes 40: 939-942
31. 31. Ahmad F, Azevedo JL, Cortright R, Dohm GL, Goldstein B (1997) Alteration in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes. J Clin Invest 100: 449-458